Press Releases ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Real-time Estimate Cboe BZX Other stock markets 02:41:53 2024-05-07 pm EDT			5-day change	1st Jan Change
8.365 ^USD	+7.11%		+4.88%	+66.93%

08:02pm	ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment	MT
May. 06	Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	08:17am	BU
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types	May. 02	BU
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA Approval in Fireside Chat at the Annual Conference of the American Urological Association	May. 01	AQ
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association	Apr. 30	BU
ImmunityBio : Investor Live Audio Webcast – ANKTIVA Post Approval	Apr. 27	PU
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer	Apr. 26	AQ
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	Apr. 25	BU
ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Apr. 23	AQ
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	Apr. 22	BU
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy	Mar. 06	BU
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study	Mar. 05	BU
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	Feb. 21	BU
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG	Feb. 05	BU
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million	Jan. 02	BU
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference	Nov. 16	BU
ImmunityBio: Q3 Earnings Snapshot	Nov. 09	AQ
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity	Nov. 07	BU
1606 Corp ($CBDW) Gears Up for the Grand Launch of Its Revolutionary AI Chatbot - ChatCBDW	23-10-31	AQ
FDA Accepts ImmunityBio's BLA Resubmission as Complete and Sets New PDUFA Date	23-10-27	AQ
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date	23-10-26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Press Releases

Filters